Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | PPARA | Q07869 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7568345 | 0.98 | GAA (0.80) | L3MBTL1GAAPPARAHSD17B10ALDH1A1 | |
| SCHEMBL13348918 | 0.98 | GAA (0.80) | L3MBTL1GAAPPARAHSD17B10ALDH1A1 | |
| SCHEMBL445511 | 0.95 | L3MBTL1 (0.76) | L3MBTL1GAAPPARAHSD17B10ALDH1A1 | |
| SCHEMBL2213697 | 0.89 | L3MBTL1 (0.72) | L3MBTL1GAAPPARAHSD17B10ALDH1A1 | |
| SCHEMBL18868405 | 0.89 | L3MBTL1 (1.00) | L3MBTL1GAAALDH1A1MAPTMAOB | |
| SCHEMBL7820115 | 0.87 | GAA (0.63) | L3MBTL1GAAPPARAHSD17B10ALDH1A1 | |
| SCHEMBL31448470 | 0.87 | PPARA (0.73) | L3MBTL1GAAPPARAPLA2G4B | |
| SCHEMBL15887752 | 0.86 | GAA (0.83) | L3MBTL1GAAPPARAALDH1A1MAPT | |
| SCHEMBL2230125 | 0.86 | PPARA (0.73) | L3MBTL1PPARAALDH1A1TP53TSHR | |
| SCHEMBL5282996 | 0.86 | L3MBTL1 (0.85) | L3MBTL1GAAPPARAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693416-B | Aryloxy aminobenzoic acid derivative, and preparation method and application thereof | 桂林医学院 | 2025-01-07 | — | — | CN | disclosed |
| CN-116693416-A | Aryloxy aminobenzoic acid derivative, and preparation method and application thereof | 桂林医学院 | 2023-09-05 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2000026262-A2 | FUNCTIONALIZED POLYMERIC SUBSTRATES FOR BINDING MOLECULAR MOIETIES | MITOKOR (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | L3MBTL1 3984/4885GAA 3114/4885PPARA 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.